Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04421027 · ClinicalTrials.gov registry record · Phase 3
A Study of Baricitinib (LY3009104) in Participants With COVID-19
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,525
- Enrollment target
NCT04421027: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT04421027 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,525 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04421027, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,525 participants
- Enrollment target
Study Summary
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
Primary Outcome
Percentage of participants who die or require non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO).
Interventions
- DRUG Placebo
- DRUG Baricitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,525 participants |
| Start Date | 2020-06-12 |
| Est. Completion | 2021-06-10 |
| Phase | Phase 3 |
What the finished NCT04421027 record still lists
NCT04421027 is an interventional study that assigns participants to a tested intervention. Its 1,525 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04421027 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04421027 about?
NCT04421027 is a clinical study titled "A Study of Baricitinib (LY3009104) in Participants With COVID-19". The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
What is the current status of trial NCT04421027?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,525 participants. The study started on 2020-06-12. Estimated completion is 2021-06-10.
What interventions are being tested in trial NCT04421027?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG).
Who is sponsoring clinical trial NCT04421027?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04421027's enrollment target sits among peer trials
1,525 155th of 2000 higher than 1,846 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06257082 · 1,526 participants · NA
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- NCT06623097 · 1,528 participants · NA
Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI